-
1.发明授权公开(公告)号：US10689438B2
公开(公告)日：2020-06-23
申请号：US14934666
申请日：2015-11-06
申请人： Novartis AG
发明人： Huixiang Zhang , Charles Boring , Alok Kulshreshtha , Yuhong Zeng , Li Wan , Laman Alani
摘要： The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
-
2.发明授权公开(公告)号：US12049495B2
公开(公告)日：2024-07-30
申请号：US16871765
申请日：2020-05-11
申请人： Novartis AG
发明人： Huixiang Zhang , Charles Boring , Alok Kulshreshtha , Yuhong Zeng , Li Wan , Laman Alani
CPC分类号： C07K16/22 , A61B3/12 , A61B5/4848 , A61K9/0048 , A61K39/3955 , A61K39/39591 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/52 , C07K2317/522 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/622 , C07K2317/76 , C07K2317/94
摘要： The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
-
3.发明申请公开(公告)号：US20200270336A1
公开(公告)日：2020-08-27
申请号：US16871765
申请日：2020-05-11
申请人： Novartis AG
发明人： Huixiang Zhang , Charles Boring , Alok Kulshreshtha , Yuhong Zeng , Li Wan , Laman Alani
IPC分类号： C07K16/22 , A61K39/395 , A61K9/00 , A61B3/12 , A61B5/00
摘要： The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
-
4.发明申请STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY 审中-公开含有抗VEGF抗体高浓度的稳定蛋白溶液配方公开(公告)号：US20160340420A1
公开(公告)日：2016-11-24
申请号：US14934666
申请日：2015-11-06
申请人： Novartis AG
发明人： Huixiang Zhang , Charles Boring , Alok Kulshreshtha , Yuhong Zeng , Li Wan , Laman Alani
IPC分类号： C07K16/22
摘要： The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
摘要翻译： 本发明提供配制为高浓度的水性药物组合物的抗VEGF抗体，其适合于注射，优选玻璃体内注射。 水性药物组合物可用于将高浓度的抗体活性成分递送至无高水平抗体聚集并且没有高水平的亚显着颗粒物质的患者。 本发明的水性组合物包含浓度为至少50mg / ml的抗体。 本发明的含水药物组合物包括糖，缓冲剂和表面活性剂。
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
